

iScience, Volume 25

## **Supplemental information**

**The integrated landscape of eRNA in gastric  
cancer reveals distinct immune subtypes  
with prognostic and therapeutic relevance**

**Xin Hu, Liuxing Wu, Yanxin Yao, Junfu Ma, Xiangchun Li, Hongru Shen, Luyang Liu, Hongji Dai, Wei Wang, Xinlei Chu, Chao Sheng, Meng Yang, Hong Zheng, Fengju Song, Kexin Chen, and Ben Liu**

## Supplemental Information

### Supplemental Table

**Table S1.** The relationship between eRNA subtypes and clinical indexes in TCGA GC cohort ( $N = 349$ ). Related to Figure 2.

TCGA	Total ( $N=349$ )	Immune_M ( $N=103$ )	Immune_H ( $N=157$ )	Immune_L ( $N=89$ )	<i>P</i>
Age					0.333
≤65	158	52	71	35	
>65	188	51	84	53	
NA	3	0	2	1	
Gender					0.135
Female	124	29	58	37	
Male	225	74	99	52	
TNM stage					0.399
Stage I - II	155	42	67	46	
Stage III-IV	180	56	82	42	
NA	14	5	8	1	
Grade					<b>0.001<sup>a</sup></b>
G1-G2	134	39	47	48	
G3	206	62	106	38	
NA	9	2	4	3	
H_pylori_infection					0.174
No	141	52	38	51	
Yes	18	7	8	3	
NA	190	44	111	35	

<sup>a</sup> Indicate statistically significant (chi-square test,  $P < 0.05$ )


**Table S2.** The relationship between eRNA subtypes and clinical indexes in GEO GC cohort (N = 964). Related to Figure 2.

GEO	Total (N=964)	Immune_M (N=142)	Immune_H (N=550)	Immune_L (N=272)	<i>P</i>
Project					0.6792
GSE15459	192	31	109	52	
GSE34942	56	11	28	17	
GSE62254	283	39	156	88	
GSE84437	433	61	257	115	
Age					0.1903
≤65	463	67	275	121	
>65	309	44	166	99	
NA	192	31	109	52	
Gender					0.9003
Female	322	46	187	89	
Male	642	96	363	183	
Stage					<b>0.0015<sup>a</sup></b>
Stage I - II	202	40	92	70	
Stage III-IV	327	40	200	87	
NA	435	62	258	115	

<sup>a</sup> Indicate statistically significant (chi-square test,  $P < 0.05$ )


# Supplemental Figure

Figure S1



**Figure S1.** The workflow of the random forest model in this study. Related to Figure 1.

**Figure S2**




**Figure S2.** The immune cells infiltration between two eRNA clusters in TCGA GC cohort.


Related to Figure 2.

**Figure S3**


**A**




**B**



**C**



**D**




**Figure S3.** K-M analysis of the high versus low eRNA score group in GEO and Tianjin cohort.

**(A)** GSE13861 cohort. **(B)** GSE26901 cohort. **(C)** GSE84437 cohort. **(D)** Tianjin cohort.

Related to Figure 7.

**Figure S4**



**Figure S4.** The validation of eRNA score in GSE93157 cohort. **(A)** Kaplan-Meier analysis of the high versus low eRNA score subgroup in the GSE93157 cohort. **(B)** The proportion of immune response to immunotherapy in high versus low eRNA score subgroups. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. Related to Figure 7.